In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

Melinda J. Reese, Paul M. Savina, Grant T. Generaux, Helen Tracey, Joan E. Humphreys, Eri Kanaoka, Lindsey O. Webster, Kelly A. Harmon, James D. Clarke, and Joseph W. Polli

Dolutegravir (DTG; S/GSK1349572) is a potent HIV-1 integrase inhibitor with a distinct resistance profile and a once-daily dose regimen that does not require pharmacokinetic boosting. This work investigated the in vitro drug transport and metabolism of DTG and assessed the potential for clinical drug-drug interactions. DTG is a substrate for the efflux transporters P-glycoprotein (Pgp) and human breast cancer resistance protein (BCRP). Its high intrinsic membrane permeability limits the impact these transporters have on DTG’s intestinal absorption. UDP-glucuronosyltransferase (UGT) 1A1 is the main enzyme responsible for the metabolism of DTG in vivo, with cytochrome P450 (P450) 3A4 being a notable pathway and UGT1A3 and UGT1A9 being only minor pathways. DTG demonstrated little or no inhibition (IC50 values > 30 μM) in vitro of the transporters Pgp, BCRP, multidrug resistance protein 2, organic anion transporting polypeptide 1B1/3, organic cation transporter (OCT) 1, or the drug metabolizing enzymes CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, UGT1A1, or 2B7. Further, DTG did not induce CYP1A2, 2B6, or 3A4 mRNA in vitro using human hepatocytes. DTG does inhibit the renal OCT2 (IC50 ≤ 1.9 μM) transporter, which provides a mechanistic basis for the mild increases in serum creatinine observed in clinical studies. These in vitro studies demonstrate a low propensity for DTG to be a perpetrator of clinical drug interactions and provide a basis for predicting when other drugs could result in a drug interaction with DTG.

Introduction

Today, the treatment of human immunodeficiency virus (HIV)-1 infection incorporates multiple agents into a combination antiretroviral therapy that targets different phases of the HIV life cycle. The Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents recommends various combination-based regimens that consist of drugs from classes that include: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors (PIs), integrase inhibitors, or C-C chemokine receptor type 5 antagonists (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012). The impact of combination therapy (e.g., highly active antiretroviral therapy) has resulted in very low to undetectable HIV RNA in serum, patients living longer, and fewer patients dying from the disease (Palella et al., 1998, 2006). This outcome changes the focus of HIV therapy from one mainly focused on managing the viral disease to one of also considering other comorbidities, including the treatment of an aging HIV population with conditions such as cardiovascular disease and diabetes. Thus, as newer HIV agents come to the market, the drug-drug interaction (DDI) assessment needs to include a broader number of co-medications than previously considered for the treatment of HIV disease.

Management of DDIs in HIV subjects is challenging, because the major mechanisms of DDIs in antiretroviral combination therapy involve cytochrome P450 (P450) enzymes, ATP-binding cassette efflux transporters, and solute carrier uptake transporters (Zembruski et al., 2011a). Most PIs (e.g., lopinavir, fosamprenavir, darunavir) are substrates or inhibitors of CYP3A4, and many of these agents require boosting with ritonavir, a very potent CYP3A4 inhibitor (Hull and Montaner, 2011). Inhibition of metabolic enzymes is not limited to only PIs or the CYP enzyme family, but other antiviral drugs such as atazanavir are potent inhibitors of both CYP3A4 and UDP-glucuronosyltransferase.
1A1 (UGT1A1) (Zhang et al., 2005). Enzyme inhibition is not the only DDI concern, as potent CYP3A4 inducers, such as the nonnucleoside reverse transcriptase inhibitors etravirine and efavirenz, can increase the metabolism of coadministered drugs, resulting in reduced exposure and efficacy (Hariprasad et al., 2004; Yanakakis and Bumpus, 2012). Finally, to add to the complexity, a single agent such as ritonavir can simultaneously be a potent inhibitor of one pathway (e.g., CYP3A4) and a potent inducer for another (e.g., CYP2C19) (Yeh et al., 2006).

In addition to metabolic enzymes, drug transporters can influence antiviral drug disposition. PIs are transported by efflux transporters such as P-glycoprotein (Pgp), human breast cancer resistance protein (BCRP), and multidrug resistance associated protein-2 transporter (MRP2) and the organic anion transporting polypeptide (OATP) uptake transporters (Dixit et al., 2007). Coadministration of Pgp or BCRP inhibitors, such as ritonavir or saquinavir, may increase the oral absorption of an HIV co-medication that is a substrate for these transporters or allow entry into more restricted tissues such as the brain or placenta. Alternatively, absorption can be reduced via induction of these transporters. Clinically significant Pgp interactions have been reported with the PIs tipranavir/ritonavir and the Pgp substrate lopamide, resulting in a 50% reduction in the area under the curve (AUC) of lopamide (Mukwaya et al., 2005).

Dolutegravir (DTG) is a tricyclic carbamoyl pyridone integrase inhibitor that blocks the strand transfer step during the integration of the HIV-1 DNA into the genome of the host cell. The unique features of DTG include a superior resistance profile and once-daily, low-milligram dosing that does not require pharmacokinetic boosting (Min et al., 2010). Like other antiretroviral agents, it is expected that DTG will be coadministered in combination with a wide variety of other drugs, including agents other than antivirals for non-HIV–related comorbidities. Because of the potential overlapping transporter and metabolic pathways of DTG and drugs coadministered to treat HIV infection or other diseases, it is critical to evaluate the potential for clinical DDIs, especially in the HIV polypharmacy setting. Therefore, the objective of this study was to investigate the mechanisms for the potential role of transporters and metabolizing enzymes in the disposition of DTG and to provide a basis for predicting when other drugs could result in a drug interaction with DTG and when DTG might cause interactions with other coadministered drugs.

Materials and Methods

GlaxoSmithKline Active Pharmaceutical Ingredient Chemistry and Analysis (Stevenage, UK) supplied [\(^{14}\)C]DTG (59 mCi/mmol), GF120918 (elacridar), and [\(^{14}\)C]cimetidine (57 mCi/mmol), [\(^{3}\)H]digoxin (5 Ci/mmol) and [\(^{3}\)H]amprenavir (19 Ci/mmol) were purchased from GE Healthcare/Amersham (Piscataway, NJ). [\(^{3}\)H]Estradiol 17β-glucuronide (EG; 50 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). Cryopreserved human hepatocytes (pool of 3 donors; 2 male and 1 female) obtained from the Netherlands Cancer Institute (Amsterdam, The Netherlands). Cell culture and transport studies were completed as previously described (Polli et al., 2008). Stock solutions of [\(^{14}\)C]DTG, GF120918 (a Pgp and BCRP inhibitor), and the positive control substrates [\(^{3}\)H]amprenavir (Pgp substrate) and [\(^{14}\)C]cimetidine (BCRP substrate) were prepared in dimethyl sulfoxide. The transport of [\(^{14}\)C]DTG and positive control substrates was measured in two directions (apical to basolateral and basolateral to apical [B→A]). DTG was tested in triplicate (0.3–100 μM). The passive membrane permeability of [\(^{14}\)C]DTG (3 μM) was determined as described previously (Polli et al., 2001, 2008) at pH 7.4/7.4 in Dulbecco’s modified Eagle’s medium (both donor and receiver sides) and at pH 5.5/7.4 or 7.4/7.4 using a biorelevant buffer (fasted state-simulated intestinal fluid on the donor side and 1% human serum albumin on the receiver side) to simulate conditions in the gastrointestinal tract; pH 5.5 was selected as the lower pH, because it provides a larger pH range that is reflective of the variability observed in the human and animal gastrointestinal tracts (Lui et al., 1986; Evans et al., 1988). The passive membrane permeability was determined in the presence of 3 μM GF120918, which was used to inhibit efflux pumps, and Lucifer yellow was included to verify monolayer integrity. Drugs were quantified by liquid scintillation counting (LSC) using a TriCarb T2900 liquid scintillation counter and Ultima Gold scintillation cocktail (PerkinElmer Life and Analytical Sciences).

Pgp and BCRP Inhibition Assays. Cell culture and transport studies were completed as described previously (Rautio et al., 2006; Polli et al., 2008). Experiments were conducted for 90 minutes using [\(^{3}\)H]digoxin (27 nM) as the probe substrate for Pgp and [\(^{14}\)C]cimetidine (80 nM) for BCRP. DTG was tested in triplicate (0.3–100 μM). [\(^{3}\)H]Digoxin and [\(^{14}\)C]cimetidine were quantified by liquid scintillation counting (LSC) using a TriCarb 2900TR liquid scintillation analyzer (PerkinElmer Life and Analytical Sciences). OCT2 ethinyl estradiol (50 μM) was determined by LSC. DTG was tested in triplicate (0.3–100 μM), and rifamycin SV (10 μM) was used as a positive control inhibitor.

Organic Cation Transporter Inhibition Assays. Organic cation transporter (OCT) 1 inhibition screening studies were conducted at Absorption Systems LP (Exton, PA) using HEK293 cells expressing OCT1. [\(^{14}\)C]Metformin (10 μM) was incubated with DTG (10 μM) or positive control inhibitor (10 μM repaglinide or 100 μM quinidine) for 10 minutes at 37°C in a humidified incubator. Incubations were performed in triplicate. Cells were lysed with 75% ethanol and radioactivity measured by LSC in a Tri-Carb 2900TR liquid scintillation analyzer (PerkinElmer Life and Analytical Sciences). OCT2 inhibition studies were conducted at Optivia (Menlo Park, CA). MDCKII cells grown on permeable supports were transfected with a vector containing OCT2. The transport of [\(^{14}\)C]metformin (10 μM) was determined by LSC. DTG was tested in triplicate (0.1–30 μM). Cimetidine was used as a positive control inhibitor (100 and 300 μM).

Identification of the Enzymes Involved in the Metabolism of DTG. [\(^{14}\)C]DTG (50 μCi/mmol) was incubated with pooled cryopreserved human hepatocytes (1.5 million cells/ml) in Weymouth’s medium containing 5% fetal bovine serum for 4 and 20 hours at 37°C in a CO2 incubator. Reactions were terminated with an equal volume of acetonitrile, samples centrifuged, and supernatants analyzed by radio-HPLC. Incubations with media but no cells served as negative controls. Positive control incubations were performed with
7-ethoxycoumarin to confirm phase I and II metabolism of the hepatocytes. The effect of a selective CYP3A4 inhibitor, azelaolin, on the metabolism of DTG was evaluated by preincubating azelaolin (5 μM) with HLMs (2 mg/ml), 0.1 M phosphate buffer, pH 7.4, and cofactor for 10 minutes before adding [14C]DTG to start the reaction. Reactions were terminated after 2 hours by adding an equal volume of acetonitrile. Control incubations were performed in the absence of azelaolin, cofactor, or HLMs. P450 reaction phenotyping experiments were conducted by preincubating Supersomes expressing individual human P450 enzymes, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 (150 pmol/ml) for 5 minutes at 37°C with [14C]DTG (5 μM) in 0.1 M phosphate buffer, pH 7.4. Reactions were initiated with the addition of cofactor (an NADPH-regenerating system consisting of 1 mM NADPH, 5.5 mM glucose-6-phosphate, and 1.2 units/ml glucose-6-phosphate dehydrogenase) and terminated after 2 hours by the addition of an equal volume of acetonitrile. Incubations were performed with no cofactor and with vector control membranes.

For UGT reaction phenotyping experiments, HLMs (1 mg/ml) were incubated with alamethicin (50 μg/mg microsomal protein) in 0.1 M Tris-HCl, pH 7.4 buffer, and 2 mM MgCl₂ for 15 minutes on ice. [14C]DTG (16 μM) was added to HLMs for 5 minutes at 37°C and reactions initiated with cofactor (5 mM UDP glucuronic acid (UDPGA)). Incubations were performed, in duplicate, for 0–4 hours. The effect of atazanavir, a UGT1A1 inhibitor (Zhang et al., 2005) on [14C]DTG glucuronidation was evaluated in HLMs preincubated with [14C]DTG (10 μM) and atazanavir (0.1–30 μM) for 5 minutes. Reactions were initiated by cofactor and incubated for 2 hours. [14C] DTG incubations with recombinant human UGT enzymes (UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, or 2B15; at 1 mg/ml protein) were conducted by activating the enzymes with alamethicin as described above. Reactions were started with UDPGA and incubations performed for 2 and 4 hours. Control incubations were performed 1) in the absence of cofactor and 2) with UGT insect cell control Supersomes (lacking UGT activity) (BD Gentest). The in vitro enzyme kinetic parameters were determined for glucuronidation of [14C]DTG (2.0, 5.0, 10, 25, 50, and 100 μM) in HLMs and human UGT1A1 enzymes. Incubations were performed for 2 hours and processes as described previously.

HPLC Radiochemical Profiling and Metabolite Identification. Radiochemical profiles of human hepatocytes, HLMs, and recombinant P450 and UGT incubations were generated using an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA) coupled with a model 625 radiochemical detector (PerkinElmer Life and Analytical Sciences) equipped with a 0.5-ml flow cell. Chromatography was performed using a Symmetry C18 Symmetry (100 × 4.6 mm, 3.5 μm) analytical column (Waters, Milford, MA) maintained at a temperature of 40°C. The mobile phase consisted of two solvents: A (aqueous 0.1% ammonium acetate) and B (acetone containing 0.1% ammonium acetate) delivered at a flow rate of 1.5 ml/min. Separations were achieved by using a gradient profile: 0–3 minutes, 5% B; 3.5–40 minutes, 5–25% B; 40–43.5 minutes, 25–35% B; 43.5–46.75 minutes, 35–95% B; 46.75–48.3 minutes, 95% B and returned to initial conditions with a 1-minute equilibration between injections. For off-line detection, the ratio of scintillation fluid (Ultima Flo M) to mobile phase was 2:1. DTG metabolites were identified by liquid chromatography-mass spectrometry/mass spectrometry using an Agilent 1100 HPLC System interfaced with a ThermoFinnigan LTQ-Orbitrap mass spectrometer (Thermo Corporation, San Jose, CA) operated in positive ion, full scan, MS/MS, or MSn modes with argon or helium as the collision gas. Leucine encephalin (approximately 0.1 μg/ml) was used as a lock mass for accurate mass measurements on the Q-Tof. The combination of retention time, accurate mass from the full scan and subsequent MS/MS or MSn scans, and comparison with spectroscopic data from other nonclinical studies (unpublished data) was used for structural identification of DTG and its metabolites.

P450 Inhibition by DTG. The potential for DTG to inhibit human P450 enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) in a direct and metabolism-dependent manner was evaluated in HLMs (0.1 mg/ml). Incubation conditions, analytical details of positive control inhibitors, and specific probe substrates for the P450 inhibition studies were conducted as described previously (Polli et al., 2012). Incubations for DTG and positive control inhibitors were tested in duplicate (0.1–100 μM). To assess direct P450 inhibition, reactions were initiated by an NADPH-regenerating system (cofactor solution consisting of 1.7 mg of NADP+, 7.8 mg of glucose-6-phosphate, and 6 U of glucose-6-phosphate dehydrogenase per milliliter). P450 metabolism-dependent inhibition (MDI) was examined by preincubating DTG with HLMs and cofactor for 20 minutes and continuing incubation with the individual probe substrate for 5–10 minutes. Reactions were terminated with a half-volume of acetonitrile containing internal standard for the reference compound and centrifuged to remove protein. Supernatants were injected onto an Inertsil 33 × 3 mm ODS-3 3-μm HPLC column (GL Sciences Inc, Torrance, CA) and analyzed by validated liquid chromatography-mass spectrometry/mass spectrometry methods using a Sciex API4000 (Applied Biosystems/MSD Sciex, Concord, ON, Canada) equipped with an electrospray ionization source as described previously (Polli et al., 2012). Analyte (probe substrate metabolite) to internal standard peak area ratios were calculated, and the metabolite concentrations were determined by interpolation from the individual standard curve. Rates of metabolite production at each concentration were expressed as a percentage of the mean uninhibited control rate for each assay. Nonlinear regression analyses of the data were performed using GraFit (v.5.0.8; Ehrithaus Software Limited, London, UK) to calculate IC50 values.

UGT Inhibition by DTG. The ability of DTG to inhibit UGT1A1 and 2B7 was evaluated by measuring the glucuronidation of scopoletin (20 μM; UGT1A1) and 7-hydroxy-4-(trifluoromethyl) coumarin (HFC; 15 μM; UGT2B7) in UGT Supersomes (BD Gentest) using fluorescence detection (Collier et al., 2000). DTG (0.1–100 μM), positive control inhibitor atazanavir (UGT1A1), or gemfibrozil (UGT2B7) was incubated in duplicate in a 96-well OptiPlate (PerkinElmer Life and Analytical Sciences) in a 0.1 M Tris-HCl pH 7.4 buffer containing 5 mM MgCl₂, probe substrate, 25 μg/ml alamethicin, and 0.25 mg/ml UGT enzymes. Reactions were initiated by 2 mM UDPGA. Sample analysis was performed using fluorescence detection with a SpectraMax M2™ microplate reader (Molecular Devices, Sunnyvale, CA). The decrease in scopoletin or HFC fluorescence due to the production of the glucuronide metabolite was monitored at excitation and emission wavelengths of 410 and 590 nm, respectively, with measurements taken every 2 min over the course of 30 min. Rates of scopoletin or HFC glucuronidation were calculated by monitoring a decrease in substrate fluorescence in the absence and presence of inhibitor and expressed as the rate (slope). Rates of metabolite production at each concentration of inhibitor were expressed as a percentage of the mean uninhibited control rate for each assay. The IC50 values were calculated using GraFit software.

Induction of P450 mRNA by DTG in Human Hepatocytes. Primary human hepatocytes from a single donor were commercially obtained placed in a sandwich configuration on a collagen substratum with Matrigel overlay (CellziDirect); three separate donors were tested. Hepatocytes were treated for 2 days with DTG (1, 5, 10, 20, 30, and 40 μM), vehicle control (0.1% dimethyl sulfoxide), or prototypical inducers, β-naphthoflavone (CYP1A2) (35 μM), phenobarbital (CYP2B6) (1 mM), and rifampicin (CYP3A4) (20 μM). After culture and test compound treatment, cells were lysed and total RNA was extracted. mRNA expression for each P450 was determined using quantitative real-time polymerase chain reaction technology (TaqMan) (Bowen et al., 2000). Relative differences in mRNA expression were assessed based on different cycling threshold values, which were determined by the ABI 7900 Real Time PCR System Sequence Detection Software (SDS v1.3).

Calculations. For monolayer efflux studies, the flux of DTG and probe substrates was calculated using the following equation:

\[ J = \frac{V}{A} \]

where \( J \) is the flux (nmol/cm²/h), \( V \) is the receptor volume (ml), \( A \) is the receiver drug concentration (nmol/ml), \( t \) is time in hours, and \( A \) is the membrane surface area (cm²).

The passive permeability of DTG, probe substrates, and Lucifer yellow in the presence of GF120918 was determined using the following equation as described previously (Rauhio et al., 2006):

\[ P_{a,k} = \frac{(-V_D V_K)}{(V_D + V_K)A} \ln \left(1 - \frac{V_D + V_K C_0(t)}{V_D C_0(t) + V_K C_0(t)}\right) \times 10^{10} \text{m}^2/\text{s} \]

where \( P_{a,k} \) is the permeability coefficient at pH 7.4, \( V_D \) and \( V_K \) are donor and receiver well volumes, respectively (ml), \( A \) is the membrane surface area (cm²), \( t \) is the incubation time (seconds), \( C_0(t) \) is the measured concentration in the...
receiver well at time \( t \) (nmol/ml), and \( C_{i0}(t) \) is the measured concentration in the donor well at time \( t \) (nmol/ml).

For transporter and P450 inhibition studies, the IC\(_{50}\) values (the concentration of inhibitor required for 50% inhibition of the monolayer transport, cellular uptake, or metabolite production rates) were calculated with GraFit (version 5.08; Erithacus Software Limited) using:

\[
y = \frac{\text{Range}}{1 + \left( \frac{x}{IC_{50}} \right)^2} + \text{background}
\]

where \( y \) = the rate of transport, uptake, or metabolite generation of an appropriate probe (expressed as a percentage of the uninhibited control), \( \text{Range} \) = the rate in the absence of test compound, \( x \) = the inhibitor concentration (\( \mu M \)), and \( \text{background} \) = the uninhibited rate (expressed as a percentage of the total rate).

Unbound hepatic inlet concentrations of atazanavir, \([I]_{\text{ATZ}}\) (0.74 \( \mu M \)), and ritonavir, \([I]_{\text{RTV}}\) (0.016 \( \mu M \)), were estimated according to methods previously described in the literature (Ito et al., 1998). The atazanavir inhibition constants (\( K_i \)) for UGT1A1 and CYP3A4 are \( K_{i,\text{ATZ,UGT1A1}} \) (0.2 \( \mu M \)) and \( K_{i,\text{ATZ,CYP3A4}} \) (2.35 \( \mu M \)), respectively (Busti et al., 2004). Ritonavir inhibition constants for CYP3A4 and UGT1A1 are \( K_{i,\text{RTV,3A4}} \) (0.03 \( \mu M \)) and \( K_{i,\text{RTV,UGT1A1}} \) (9.5 \( \mu M \)) (Zhang et al., 2005; Granfors et al., 2006). The \( K_{i,\text{RTV,UGT1A1}} \) was estimated by dividing the reported IC\(_{50}\) value in half, assuming competitive inhibition. \( F_s \), the fraction of substrate escaping gut-wall metabolism, was assumed to be 1 based on DTG’s in vitro CL, and high passive permeability. \( f_{m,n} \) is the fraction of the substrate dose metabolized by a specific enzyme (e.g., CYP3A4 or UGT1A1).

Results

ATP-Binding Cassette Transporter Substrate Assays. To determine whether \( [^{14}C] \)DTG is a substrate for human Pgp or BCRP, the in vitro bidirectional transport across MDCKII monolayers expressing these transporters was studied. In addition, the passive permeability was determined by inclusion of GF120918, a Pgp and BCRP inhibitor. The efflux ratio for \( [^{14}C] \)DTG across the MDCKII-MDR1 monolayers was 3.8 and decreased to 0.74 in the presence of GF120918, consistent with DTG being a substrate for Pgp (Table 1). For BCRP, the efflux ratio of \( [^{14}C] \)DTG across the MDCKII-BCRP monolayers was 3.1 and decreased to 0.80 in the presence of GF120918 (Table 1), consistent with DTG being a substrate for BCRP. The in vitro passive membrane permeability of \( [^{14}C] \)DTG across the MDCKII monolayers was 333 nm/s (\( P_{50} \) B→A + GF120918) using Dulbecco’s modified Eagle’s medium as the transport buffer and was 265 (\( P_{50} \) (baso)) and 252 (\( P_{50} \) (apo)) nm/s using fasted state-simulated intestinal fluid buffer, at pH 5.5/7.4 (donor/receiver) and 7.4/7.4, respectively. These results demonstrate that DTG has high membrane permeability independent of pH.

ABC and Solute Carrier Transporter Inhibition Assays. The inhibition of Pgp and BCRP by DTG was assessed by determining the B→A transport of \([^{3}H] \)digoxin and \([^{14}C] \)cimetidine across MDCKII-MDR1 or MDCKII-BCRP monolayers, respectively. DTG at a concentration of 100 \( \mu M \) decreased the Pgp-mediated transport of \([^{3}H] \)digoxin by 29% and inhibited BCRP-mediated transport of \([^{14}C] \)cimetidine by 43% at 30 \( \mu M \) and 50% at 100 \( \mu M \). However, due to solubility limitations of DTG, an IC\(_{50}\) value could not be determined (Table 2). MRP2 inhibition by DTG and its ether glucuronide, M2, was assessed by measuring the uptake of \([^{3}H] \)EG in Chinese hamster ovary cell line heterologously expressing the human OATP1B1 transporter and HEK-MSRII-OATP1B3 cells, respectively. At all concentrations tested (0.1–100 \( \mu M \)), no inhibition of \([^{3}H] \)EG uptake in MRP2 vesicles was observed (IC\(_{50} > 100 \mu M \); Table 2).

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Results of transport studies for ( [^{14}C] )DTG (3 ( \mu M )) in MDCKII-MDR1 or MDCKII-BCRP cell monolayers*</td>
</tr>
<tr>
<td>MDCKII Cell Line</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>MDR1</td>
</tr>
<tr>
<td>MDR1</td>
</tr>
<tr>
<td>MDR1</td>
</tr>
<tr>
<td>BCRP</td>
</tr>
</tbody>
</table>

* Data are the mean ± S.D. from three monolayers over 90 min using Dulbecco’s Modified Eagle’s medium as the transport buffer. All donor compartments contained Lucifer yellow (100 \( \mu M \)) to determine monolayer integrity (pass criterion \( P_{74} ≤ 50 \text{ nmol/s} \)). Amprenavir served as a positive control for Pgp efflux and cimetidine for BCRP efflux. The measured radiochemical purity of \( [^{14}C] \) DTG was >99% and no metabolic or chemical degradation was detected during the studies.

\( ^{b} \) GF120918 was used in both donor and receiver compartments at 2 \( \mu M \) for Pgp and BCRP.
TABLE 2

<table>
<thead>
<tr>
<th>Transporter</th>
<th>IC50</th>
<th>Substrate</th>
<th>[I1] IC50</th>
<th>[I2] IC50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pgp</td>
<td>&gt;100</td>
<td>[3H]Digoxin</td>
<td>&lt;0.08</td>
<td>&lt;5</td>
</tr>
<tr>
<td>BCRP</td>
<td>&gt;30</td>
<td>[14C]Cimetidine</td>
<td>&lt;0.26*</td>
<td>&lt;16**</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>&gt;100</td>
<td>[3H]Estradiol 17β-α-glucuronide</td>
<td>&lt;0.08</td>
<td>n/a</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>&gt;100</td>
<td>[3H]Estradiol 17β-α-glucuronide</td>
<td>&lt;0.08</td>
<td>n/a</td>
</tr>
<tr>
<td>MRP2</td>
<td>&gt;100</td>
<td>[3H]Estradiol 17β-α-glucuronide</td>
<td>&lt;0.08</td>
<td>&lt;5</td>
</tr>
<tr>
<td>OCT1</td>
<td>NC</td>
<td>[14C]Metformin</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>OCT2</td>
<td>1.9 (0.29)</td>
<td>[14C]Metformin</td>
<td>4.2*</td>
<td>n/a</td>
</tr>
</tbody>
</table>

* [I1] = 8 μM with DTG clinical daily dose of 50mg (Song et al., 2010); **Possible DDI risk based on [I2] > 10 as described in (Zhang et al., 2010); Giacomini et al., 2010).
* a Not calculated; DTG at a concentration of 10 μM inhibited OCT1 by 22%.
* b n/a = not applicable; transporter not (highly) expressed in the gastrointestinal tract (Hilgendorf et al., 2007).

The estimated kinetic parameters, $K_m$, $V_{max}$, and $CL$, for M2 formation in HLMS were 149 μM, 409 pmol/min per mg, and 2.7 μl/min/mg, respectively (Fig. 3A), and for the recombinant human UGT1A1 enzyme were 21 μM, 67 pmol/min/mg, and 3.2 μl/min/mg, respectively (Fig. 3B).

The oxidative metabolism of [14C]DTG (5 μM) was studied in NAPDH-fortified HLMS and recombinant P450 enzymes. An oxidative metabolite (M3) was formed in recombinant CYP3A4 incubations (Fig. 2C) with an $CL_{int}$ of 3.0 μl/min/mg, and its formation was completely inhibited by azamulin, a selective CYP3A4 inhibitor. M3 was also observed in HLM incubations, and its formation was completely inhibited by azamulin, a selective CYP3A4 inhibitor. In addition, an N-dealkylated metabolite (M1), which is a hydrolysis product of M3, was observed in the CYP3A4 incubations. No DTG metabolites were observed in CYP1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 incubations, indicating that CYP3A4 is the primary P450 enzyme involved in the oxidative metabolism of DTG in vitro. The overall metabolic profile for DTG is summarized in Fig. 4.

P450 and UGT Inhibition by DTG. The inhibition of human P450 enzymes by DTG was evaluated using HLMS and selective P450 probe substrates (Table 3). DTG inhibited CYP2B6, 2C9, 2C19, 2D6, and 3A4 (nifedipine), but the percentage of inhibition observed (range 20–40%) at the highest concentration tested (100 μM) was weak and insufficient to calculate an IC50. In contrast, DTG inhibited CYP3A4-mediated metabolism of atorvastatin with a calculated IC50 of 54 μM (Table 3). DTG did not inhibit CYP1A2, 2A6, or 2C8 (IC50 > 100 μM; Table 3). CYP3A4 MDI was observed for nifedipine and atorvastatin with decreases in IC50 values following cofactor preincubation. DTG was not a metabolism-dependent inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, or 2D6.

The inhibition of human UGT1A1 and 2B7 enzymes by DTG was evaluated by measuring the enzyme activities of scopoletin and 7-HPC in recombinant human UGT1A1 and 2B7 enzymes, respectively, using fluorescence detection. DTG was not an inhibitor of UGT2B7 at concentrations up to 100 μM. Weak inhibition of UGT1A1 was observed; however, inhibition (33%) at the highest concentration tested was insufficient to calculate an IC50 value (IC50 > 100 μM).

P450 Induction by DTG. The potential of DTG to induce CYP1A2, 2B6, and 3A4 mRNA was assessed in primary cultured human hepatocytes using TaqMan technology. After incubation for 48 h with DTG (1–40 μM), there was no notable induction of CYP1A2, 2B6 or 3A4.

Discussion

The studies presented herein describe the in vitro disposition and metabolism of DTG and the potential for DTG to be a victim or perpetrator of DDIs via modulation of transporters or metabolizing enzymes. Similar to other antiretroviral agents, DTG will be coadministered in combination with a variety of other drugs. Therefore, assessment of potential DDIs is an essential aspect in the clinical development of DTG.

Based on the limited aqueous solubility and high permeability, DTG is a Biopharmaceutics Drug Disposition Classification System class 2 drug (Benet et al., 2008, 2011), where efflux transporters and metabolizing enzymes are predicted to be important in the drug’s disposition. Indeed, in vitro studies show that DTG undergoes extensive metabolism and is a substrate for Pgp and BCRP, two transporters reported to influence the intestinal absorption and central nervous system penetration of HIV drugs (Kivisto et al., 2004). Although DTG is a substrate for efflux transporters, it exhibits rapid oral absorption ($T_{max}$ ~ 2 h following a 50-mg dose) and dose-proportional kinetics.
In a human mass balance study where healthy subjects received 20 mg of [14C]DTG, 31.6% of the total oral dose was excreted in the urine, represented mainly by an ether glucuronide (M2, 18.9% of total dose), N-dealkylation (M1, 3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (M3, 3.0% of total dose) (unpublished data). Fecal elimination contributed an additional 3.1%, resulting in approximately 10% of the metabolism of DTG being represented by oxidative products. On the basis of the fraction of the dose renally eliminated and the CLs values determined from in vitro UGT and CYP3A4 studies, the fraction of DTG metabolized by UGT1A1 (f_{m,UGT1A1}) and CYP3A4 (f_{m,CYP3A4}) is estimated to be 0.51 and 0.21, respectively. The fraction of DTG metabolized by UGT1A3 and 1A9 is estimated at 0.028 and 0.055, respectively. It should be noted that the estimates of f_{m,UGT} may be underestimated due to the instability of the ether glucuronide in feces, as the conjugate may hydrolyze and convert back to parent drug under these conditions. Since DTG is a substrate for UGT1A1 and CYP3A4, pharmacokinetic interactions involving coadministration of a UGT1A1 or CYP3A4 inhibitor or inducer could perturb the pharmacokinetics of DTG. Based on the fraction of DTG metabolized, an interaction with UGT1A1 and CYP3A4 inhibitors may be expected if both pathways are fully inhibited (combined f_{m} = 0.72). Ritonavir and atazanavir are HIV PIs that have been coadministered with DTG (Song et al., 2011a). Both are potent CYP3A4 inhibitors and atazanavir is also a marked UGT1A1 inhibitor. Using a mechanistic static equation (see Materials and Methods) and the estimated f_{m} above, the AUC of DTG was expected to increase by as much as 1.8- to 2.0-fold when coadministered with ritonavir-boosted atazanavir. Indeed, when DTG was co-dosed with 400 mg of atazanavir in a clinical study, there was a 1.9- and 1.5-fold increase in DTG AUC(0-t) and C_{max}, respectively (Song et al., 2011a). When dosed with atazanavir/ritonavir (300/100 mg), the DTG AUC(0-t) and C_{max} increased 1.62- and 1.34-fold. These data are consistent with UGT1A1 and CYP3A4 being the important pathways of DTG metabolism in vivo, with UGT1A3 and UG1A9 having minor roles in DTG clearance.

In contrast to inhibition of metabolic pathways, metabolic inducers such as rifampin, etravirine, efavirenz, and tipranavir need to be considered, as they are important agents in the treatment of HIV and other infectious diseases. It is also known that strong activators of human pregnane X receptor can lead to increased metabolic activity for UGT1A1, CYP3A4, and transporters (Chen et al., 2012). Induction of these pathways could increase the systemic clearance of DTG, resulting in lower exposures. Both etravirine and efavirenz reduce the AUC(0-t) of DTG by 71% and 57%, respectively (Song et al., 2011b,c). This interaction with DTG is likely the combined effect of UGT and CYP3A4 induction. This is consistent with etravirine and efavirenz causing modest decreases (20–40%) in the pharmacokinetics of raltegravir, a sensitive UGT substrate (Kassahun et al., 2007; Iwamoto et al., 2008). Support for a role of CYP3A4 induction was demonstrated by coadministration of the potent CYP3A4 inhibitors lopinavir/ritonavir or darunavir/ritonavir that counteracted the decrease in DTG exposure by etravirine (Song et al., 2011c). Alternatively, the decreases in DTG exposure could also involve drug transporters. One interesting possibility is (modest) MRP2 inhibition leading to a partial disruption in the enterohepatic recirculation of DTG; both etravirine and efavirenz are inhibitors of MRP2 (Zembruski et al., 2011b).

At clinically relevant concentrations, DTG does not result in drug interactions by inhibition or induction of P450 enzymes or UGT1A1/2B7 inhibition. Although DTG demonstrated weak CYP3A4 MDI of with low to moderate variability (Min et al., 2010). These data suggest that the high intrinsic passive membrane permeability attenuates any impact efflux transporters may have on DTG’s intestinal absorption in humans. This is further supported by clinical studies that have demonstrated no clinically significant change in DTG pharmacokinetics when coadministered with lopinavir/ritonavir (Song et al., 2011d), which are known Pgp and BCRP inhibitors.

---

**Fig. 2.** Formation of DTG metabolites by recombinant UGT and human P450 enzymes. (A) Formation of DTG glucuronide metabolite (M2) in UDPGA-fortified recombinant human UGT enzyme and HLM incubations. [14C]DTG (16 μM) incubated for 120 min at 1 mg/ml HLM protein. (B) Effect of atazanavir on [14C]DTG glucuronidation in UDPGA-fortified HLMs. [14C]DTG (10 μM) was incubated with HLMs (1 mg/ml protein) for 120 min. (C) M1 and M3 formation in NADPH-fortified human P450 enzyme and HLM incubations. [14C]DTG (5 μM) was incubated for 120 min with 150 pmol/ml P450 enzyme or 2 mg/ml HLMs.
nifedipine and atorvastatin in vitro (approximately 1.6-fold reduction in \( IC_{50} \); Table 3), a clinical study demonstrated that DTG had no effect on midazolam’s pharmacokinetics (Min et al., 2010), confirming that DTG does not inhibit or induce \( \text{CYP3A4} \) in vivo.

The DTG IC\(_{50}\) values for all transporters examined were >30 \( \mu M \) except for OCT2 (discussed below). These IC\(_{50}\) values are higher than the peak plasma concentration of DTG following a 50-mg daily dose (3.45 \( \mu g/ml \), 8 \( \mu M \)) (Song et al., 2010), supporting the overall low potential for transporter-mediated drug interactions (\([I_{1,\text{total}}]/IC_{50}\); Table 2) (Zhang et al., 2008; Giacomini et al., 2010). Further, the overall drug interaction risk is even lower due to the high plasma protein binding (>99%) of DTG (unpublished data). Finally, calculation of inhibition of efflux transporters in the intestine following a 50-mg dose supports a limited risk of DDIs as \([I_2]/IC_{50}\) values for both Pgp and MRP2 are <5 (Table 2) (Zhang et al., 2008; Giacomini et al., 2010). However, based on the \([I_2]/IC_{50}\) value for BCRP likely being close to 10, there could be a small risk of inhibition of this transporter by DTG. Our findings are consistent with in vitro data reported by Lepist et al. (2011) indicating that DTG is a weak or noninhibitor of Pgp (IC\(_{50}\) > 90 \( \mu M \)), MRP2 (IC\(_{50}\) > 90 \( \mu M \)), and BCRP (IC\(_{50}\) = 67 \( \mu M \)). Overall, the data support a low potential for DTG to cause clinically significant DDIs with other drugs such as simvastatin, rosuvastatin, and atorvastatin (OATP, BCRP, and P450 substrates), and metformin (OCT1/2 substrate). A clinical study with tenofovir, an OAT and MRP4 substrate (Ray et al., 2006), demonstrated no interaction of DTG on tenofovir pharmacokinetics (Song et al., 2010), suggesting that DTG is not an inhibitor of these transporters in vivo.

In contrast to the other transporters discussed, DTG causes notable in vitro inhibition of the renal transporter OCT2 (IC\(_{50}\) = 1.9 \( \mu M \)). As this value is 4-fold lower than the \( C_{\text{max}} \) of DTG (\([I_{1,\text{total}}]/IC_{50}\) = 4.2), a potential interaction exists for compounds that undergo renal secretion via OCT2, such as circulating serum creatinine (a product of muscle turnover) and the anti-arrhythmic drug dofetilide. The in vitro OCT2 inhibition data are consistent with the mild 10–14% decreases in serum creatinine clearance observed in patients administered DTG (Koteff et al., 2011; van Lunzen et al., 2012). These mild, reversible changes are similar to other clinical observations with OCT/MATE inhibitors such as dronedarone, AZD0837, and DX-619 (Sarapa et al., 2007; Tschuppert et al., 2007; Schutzer et al., 2010; Imamura et al., 2011). A clinical study confirmed that the changes in creatinine were not due to DTG altering renal blood flow or renal clearance; therefore,

---

**Fig. 3.** Michaelis-Menten kinetic plots for DTG glucuronidation. HLMs (A) and human (B) UGT1A1 enzyme incubations were conducted for 120 min with 1 mg/ml microsomal protein. Single incubations were run for 25 and 50 \( \mu M \) concentrations of DTG in UGT1A1 incubations only.

**Fig. 4.** Metabolic scheme of DTG.
TABLE 3
Inhibition of CYP enzymes by DTG in HLMs

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Control Preincubation IC50</th>
<th>NADPH Preincubation IC50</th>
<th>Fold Change in IC50</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYPI2A Phenacetin</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2A6 Coumarin</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2B6 Bupropion</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2C8 Rosiglitazone</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2C9 Diclofenac</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2C19 S-Mephentynol</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 2D6 Bufuralol</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>NC</td>
</tr>
<tr>
<td>CYP 3A4 Atorvastatin</td>
<td>54</td>
<td>33</td>
<td>1.6</td>
</tr>
<tr>
<td>CYP 3A4 Neflupidine</td>
<td>&gt;100 NC</td>
<td>&gt;100 NC</td>
<td>&gt;1.5</td>
</tr>
</tbody>
</table>

NC, not calculated.

a: Micromolar (0.1 mg/mL), buffer and DTG preincubated for 20 minutes with probe substrate prior to initiation of reaction with NADPH.

b: Micromolar (0.1 mg/mL), buffer and DTG preincubated for 20 minutes with NADPH prior to initiation of reaction with probe substrate.

c: Control preincubation IC50 = direct inhibition IC50.

d: 50% inhibition was observed but the percentage of inhibition at the highest DTG concentration tested (100 μM) was weak (20–40%) and insufficient to calculate an IC50.

The changes in creatinine serum levels are likely due to the inhibition of the OCT2 transporter (Schutzer et al., 2010; Koteff et al., 2011; Kusuhara et al., 2012). Caution with concomitant dosing of DTG and dofetilide, a narrow therapeutic index class III antiarrhythmic agent, is warranted, as OCT2 inhibition can significantly reduce its renal clearance as shown by a clinical interaction with cimetidine (Roukoz and Saliba, 2007). However, there is less concern for other OCT substrates, such as metformin, as these drugs have larger therapeutic windows compared with dofetilide. In addition, the lack of significant inhibition of OCT1 allows transport of metformin to the liver, its site of action, to maintain its pharmacological effect.

In conclusion, these in vitro studies reveal the low propensity of DTG to cause drug interactions through metabolic or transporter pathways, consistent with the lack of clinical interactions observed to date with DTG. Further, these studies provide a mechanistic explanation for the DDIs observed with DTG when coadministered with CYP, UGT, and transporter inhibitors and/or inducers. As a result of the multiple clearance pathways of DTG, few clinically significant alterations in DTGs pharmacokinetics have been observed that require a dose adjustment. This is consistent with the current safety profile of DTG in humans.

Acknowledgments

The authors thank Jane Rosemond, Bishop Jethro, Masuma Naqwe, John Ulrich, Jo Salisbury, and Lindsey Harston for their technical support, Gary Bowers for review of this manuscript, and also colleagues at GlaxoSmithKline who encouraged and supported this study.

Authorship Contributions

Participated in research design: Reese, Savina, Generaux, Tracey, Humphreys, Kanoaka, , Webster, Harmon, Clarke, Polli.

Conducted experiments: Reese, Humphreys, Tracey, Webster, Clarke, Harmon, Generaux.

Performed data analysis: Reese, Savina, Generaux, Tracey, Humphreys, Webster, Harmon, Clarke, Polli.

Wrote or contributed to the writing of the manuscript: Reese, Savina, Generaux, Tracey, Kanoaka Polli.

References

fluorobenzoyl[oxoy]phenyl-6-[5-(2-methylsulfonyl)ethyl]aminomethyl]-2-furyl]-4-quinazolinamine
(GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 36:695–701.
Nunez DJ (2013) Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with
Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Sarabjit-Singh CJ,
interaction potential of new drug candidates: a recommendation for probe substrates. Drug
Metab Dispos 34:786–792.
Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ,
elevations of serum creatinine levels but no effect on glomerular filtration during treatment with
in combination therapy in antiretroviral-naive adults with HIV: planned interim
effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/
Effect of drot糌aronore in renal function in healthy subjects. Br J Clin Pharmacol 64:
792–792.
Yanakakis LJ and Bumpus NN (2012) Biotransformation of the antiretroviral drug etravirine:
metabolite identification, reaction phenotyping, and characterization of autoinduction of cy-
of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J
Zembruski NC, Haefeli WE, and Weiss J (2011b) Interaction potential of etravirine with drug
Zhang D, Chando TJ, Everett DW, Patten CJ, Dohal SS, and Humphreys WG (2005) In vitro
inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors
and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos
33:1729–1739.
Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on
transporter-based drug interactions. Xenobiotica 38:769–784.